Impact of SGLT2-inhibitors on kidney injury in heart patients
Official title: Impact of SGLT2-inhibitors on Post Contrast Acute Kidney Injury in Acute Coronary Syndrome Patients Receiving Invasive Strategy
Run by Shenyang Northern Hospital · NCT06491953 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing whether a type of diabetes medication can help protect the kidneys of heart patients from injury during certain medical procedures.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 3600 (estimated) |
| Sponsor | Shenyang Northern Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06491953 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 to 80 with acute coronary syndrome who are scheduled for invasive treatments like PCI.
✕Probably not a fit
Patients with severe renal insufficiency, type 1 diabetes, or contraindications to SGLT2-inhibitors are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the effects of SGLT2-inhibitors on post-contrast acute kidney injury (PC-AKI) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). The study aims to determine whether these oral antidiabetic medications can mitigate the risk of kidney injury associated with the use of iodine-based contrast agents during invasive cardiac procedures. By analyzing data from ACS patients, the research seeks to provide insights into the renal protective effects of SGLT2-inhibitors in this specific clinical context.
Why it matters
Potential benefit: If successful, this study could lead to improved kidney protection strategies for heart patients undergoing invasive procedures.
How similar studies have gone: Previous studies have shown that SGLT2-inhibitors can improve renal function and reduce cardiovascular risks, suggesting potential success in this novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ACS patients undergoing invasive treatment (PCI or CAG) * 18 \~ 80 years old adult patients * Written informed consent provided Exclusion Criteria: * Administration of any iodinated CM within 14 days before CAG or PCI * Hepatic dysfunction (ALT 3 times greater than upper normal limit) * Thyreoid insufficiency * Renal artery Stenosis (unilateral \>70％ or bilateral stenosis\>50％) * Known allergy to any of the study drugs or devices (iodinated CM, etc.) * Pregnancy or lactation * Contraindications for the use of SGLT-2 inhibitors, such as severe renal insufficiency (eGFR \<30 mL/min/1.73m2 or currently on dialysis), type 1 diabetes mellitus, severe infection, etc.) * Any condition which might interfere with study compliance, or otherwise unsuitable for study participation as judged by the investigators
Where it's running
-
General Hospital of Northern Theater Command
Shenyang, Liaoning, China Recruiting
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.